Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2023-11-07 Major Shareholding Noti…
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
112年11月僑外投資持股
Major Shareholding Notification Classification · 95% confidence The document is a statistical table showing changes in shareholding by overseas and mainland China investors, specifically indicating a cash capital increase and updated shareholding numbers. It includes details on share counts before and after the change, and references to regulatory approvals. The document length is short (1082 characters) and it primarily reports shareholding changes related to capital increase. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. It is not an announcement of a report, nor a full financial report, nor a certification or legal proceeding. Therefore, the best classification is MRQ.
2023-11-07 Chinese
公告本公司112年現金增資收足股款暨增資基準日。
Capital/Financing Update Classification · 95% confidence The document is a short announcement (756 characters) from a company (旭富製藥科技股份有限公司) regarding the completion of a cash capital increase and the setting of the capital increase base date. It includes details such as the number of shares issued, subscription price, total amount raised, and the date of the capital increase base. There are no financial statements or detailed financial analysis present. The document is an update on a financing activity rather than a full report. According to the classification rules, such announcements about fundraising or capital structure changes fall under Capital/Financing Update (CAP). The document is not a full report, nor is it a regulatory filing or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2023-11-06 Chinese
本公司112年現金增資股款催繳公告。
Capital/Financing Update Classification · 95% confidence The document is a short announcement (958 characters) regarding the company's cash capital increase payment collection deadline and related procedures. It details the deadline for shareholders and employees to pay for newly issued shares and the consequences of non-payment. There is no financial statement, detailed financial data, or comprehensive report content. The document is an update on a capital raising event, specifically about the collection of subscription payments for a cash capital increase. This fits the category of Capital/Financing Update (CAP).
2023-10-30 Chinese
112年9月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (旭富) providing information about fund loans and endorsement guarantees, with specific monthly and cumulative amounts, all reported as zero. The content is a regulatory disclosure of financial guarantees and related credit information, typical of a regulatory filing rather than a full financial report or announcement. The document length is short (601 characters), and it does not contain financial statements or detailed analysis. It is not an announcement of a report but a direct regulatory disclosure. Therefore, the best fitting category is Regulatory Filings (RNS).
2023-10-06 Chinese
112年9月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summarized revenue report for a company named 旭富, showing monthly and cumulative net operating revenue figures with comparisons to the previous year. It includes notes on accounting standards (IFRS) and reporting practices. The document length is short (770 characters) and it primarily provides financial data for a specific month and year (September 2023). It does not contain a full financial report or detailed analysis, but rather a brief financial summary. This fits the definition of a Fund Information / Factsheet (FS), which is a brief summary of key company financials and market info.
2023-10-06 Chinese
公告變更本公司廢水處理設施合約金額。
Regulatory Filings Classification · 95% confidence The document is a short announcement (831 characters) from a listed company (4119 旭富) regarding a change in contract amount for wastewater treatment facilities. It includes details about the original contract, the reason for the change, and the financial impact, which is minor. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. It is a regulatory announcement about a contract change, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories like Capital/Financing Update or Financial Supplement Data. The document is not a report itself but a regulatory disclosure of a contract amendment.
2023-10-06 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.